| Literature DB >> 23990980 |
He Cao1, Lu Zhang, Liping Li, Singkai Lo.
Abstract
BACKGROUND: Acute endophthalmitis is one of the most serious complications of cataract surgery and often results in severe visual impairment. Several risk factors for acute postoperative endophthalmitis (POE) following cataract surgery have been reported but the level of evidence and strength of association is varied. The purpose of this study was to critically appraise published reports on and to summarize clinical risk factors associated with acute POE which could be easily assessed by ophthalmologists for the introduction and implementation of preventive measure.Entities:
Mesh:
Year: 2013 PMID: 23990980 PMCID: PMC3753305 DOI: 10.1371/journal.pone.0071731
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Potential 45 risk factors for endophthalmitis following cataract surgery were identified in the initial review.
|
|
| • Male gender* |
| • Older individuals ( ≥85 years ) * |
| • Black race |
| • Native Americans |
| • Diabetes mellitus |
| • Recent tamsulosin exposure ( <14 days before surgery) |
| • Same day surgery |
| • Inpatient surgery |
| • Outpatient surgery |
| • Dedicated ophthalmic theatre |
| • Private hospital |
| • Preoperative topical antibiotics |
| • Residence inside of city |
|
|
| • Surgeons with low annual volume ( 1∼50 surgeries ) |
| • Surgeons with less experience ( 1∼10years ) |
| • Consultant grade surgeon |
| • Surgeries performed in 2003 |
| • Face masks not worn in theatre |
| • Skin disinfection type ( 5% povidone-iodine ) |
| • Conjunctival disinfection type ( without povidone-iodine ) |
| • Topical anesthesia |
| • Region of cataract surgery: region 6 and 9 |
| • Surgery longer than 45 minutes |
| • Without intracameral cefazolin* |
| • Without intracameral cefuroxime* |
| • Without fourth-generation fluoroquinolones |
| • Without intracameral vancomycin |
| • Without subconjunctival antibiotics at the end of surgery* |
| • Posterior capsular rupture* |
| • Intraoperative complications* |
| • A clear corneal incision* |
| • Silicon based IOL* |
| • Polymethyl methacrylate based IOL |
| • Foldable IOL |
| • Communication between the anterior and vitreous |
| • Nonadministration of subconjunctival antibiotics |
| • Extra- or intracapsular cataract extraction* |
| • Other eye procedures during the same admission ( vitreoretinal procedure, lacrimal/eyelid procedures or adjunctive MMC for inferior filtration) |
| • Phacoemulsification |
|
|
| • Wound leak on the first postoperative day |
| • Topical antibiotic started the day after surgery |
| • Use of ciprofloxacin rather than ofloxacin topically after surgery |
| • Not patching after surgery |
| • Not placing a collagen shield soaked in antibiotic |
| • Length of stay ( ≥8 days ) |
*Results were put into meta-analysis.
Figure 1Flow diagram showing the selection process for inclusion of studies in the meta-analysis.
CI = confidence interval.
Summary of the included studies evaluating risk factors and the association with acute endophthalmitis following cataract surgery.
| Authors, Year [Ref] | Data Source | Study Design | Presentation interval(days) | Country | Date | Population Sample size, age[yrs] | Total Number of endophthalmitis (incidence rate%) | Definition of the endophthalmitis | Type of confirmed pathogen (n) | Risk factors (RR/OR) & | Classification of cataract surgery | Quality Criteria? |
| Das T, 2012 | ED | CC | 15±12 | India | 1993∼ 1998 | 46 095 42∼81 | 62(0.13%) | Suspected (62) Confirmed (36) | S. Epidermidis(16); P. Aeruginosa(5); GPC (other)# (8) Others(7) | OR: Ambulatory patients care (3.63) Residence location within city(2.27) | ECCE Phacoemulsification | B |
| Keay L, 2012 | ED | RO | NR | USA | 2003∼ 2004 | 3 280 966 NA | 4 006 (0.012%) | Suspected (4006) | NR | RR: Male (1.23) Older individuals(≥85)(1.53) Black (1.17) Native Americans (1.72) Surgeons with low annual volume (3.8) Surgeons with less experience (1.41) surgeries performed in 2003 (1.2) | NA | B |
| Romero-Aroca P, 2012 | ED | PO | 5.37±2.33 | Spain | 1996∼ 2009 | 25 001 53∼89 | 83 (3.32%) | Suspected (83) Confirmed (55) | NR | RR: Without intracameral cefazolin (11.45) | Phacoemulsification | A |
| Tan CS, 2012 | ED | Coh | NR | Singapore | 11 years | 50 177 NR | 21(0.042%) | Suspected(21) | NR | OR: Without intracameral cefazolin (13.6) Age(1.05) Male gender(2.96) | NA | B |
| García-Sáenz MC 2010 | ED | CS | NR | Spain | 1999∼ 2009 | 15 173 NR | 43(0.28%) | Suspected (43) | NR | RR: Without intracameral cefuroxime (8.57) | NA | A |
| Anijeet DR, 2010 | ED | RO | 1∼14 | UK | 1998∼ 2008 | 16 606 NR | 14(0.078%) | Suspected(14) Confirmed(6) | GPC#(1); P. Streptococcus(3) P. aeruginosa (1); Nil(1) | RR: without intracameral vancomycin (38) | NA | B |
| Freeman EE 2010 | ED | RO | <90 | Canada | 1996∼ 2005 | 490 690 NR | 754(0.15%) | Suspected(754) | NR | OR:Older individuals(≥85)(1.34) Male gender(1.44) later year of surgery (0.94) Region of surgery 6 and 9(6∼9) | NA | B |
| Lloyd JC, 2009 | ED | RO | 1∼35 | Canada | 2006∼ 2005 | 13 931 NR | 5(0.036%) | Suspected(5) Confirmed(4) | Staphylococcus(2); Streptococcus(1);P.acnes(1); | OR:Without fourth-generation fluoroquinolones perioperatively(6.3) | Phacoemulsification | B |
| Al-Mezaine HS, 2009 | ED | RO | NR | Arabia | 10 | 29 412 NR | 20(0.068%) | Suspected(20) Confirmed(18) | Staphylococcus (7); Streptococcus(7); P.acnes(1); others(3) | OR:clear corneal incision(1.73) | ECCE Phacoemulsification | B |
| Garat M, 2009 | ED | CC | NR | Spain | 2002∼ 2007 | 18 579 NR | 31(0.167%) | Suspected(27) Confirmed(4) | NR | RR: Without intracameral cefazolin(8.89) | Phacoemulsification | B |
| Hatch WV, 2009 | ED | Coh | NR | Canada | 2002∼ 2006 | 442 177 NR | 617(0.14%) | Suspected(617) | NR | OR: Male gender(1.4) Capsular rupture(9.56) Older individuals(1.24) | ECCE Phacoemulsification | A |
| Pleyer U, 2008 | ED | Coh | NR | Europe | NR | 16211 NR | 29(0.179%) | Suspected(29) Confirmed(20) | NR | RR: Without intracameral cefuroxime(4.92) Clear corneal incision(5.88) Silicon based IOL(3.13) Intraoperative complications(4.95) | Phacoemulsification | A |
| Garcia-Arumi J, 2007 | ED | CC | <30 | Spain | 2002∼ 2003 | 5 011 NR | 27(0.539%) | NR | NR | OR: Topical anesthesia(11.8) Surgery longer than 45minutes(7.2) | NA | A |
| Endophthalmitis Study Group, 2007 | ED | Coh | NR | Austria, Belgium, Germany, Italy, etc. | NR | 16 603 NR | 29(0.175%) | Suspected(29) Confirmed(20) | NR | OR: Without intracameral cefuroxime (4.92) Clear corneal incision(5.88) Silicone IOL(3.13) Surgical complications(4.95) Male gender(2.70) | ECCE Phacoemulsification | A |
| Lundström M 2007 | ED | PO | NR | Sweden | 2002∼ 2004 | 225 471 NR | 109(0.048%) | Suspected(109) | NR | RR: Communication between the anterior and vitreous Older individuals (≥85) Without intracameral cefuroxime | ECCE Phacoemulsification | A |
| Ng JQ, 2007 | W | CC | NR | Australia | 1980∼ 2000 | 1 025 NR | 205(NA) | Suspected (205) | NR | RR: Same day surgery (2.27) Posterior capsule breach(13.57) Sub-conjunctival injection(0.46) | ECCE Phacoemulsification | B |
| Kamalarajah S, 2006 | ED | CC | NR | UK | 1999∼ 2000 | 659 (73.5–75) | 214(NA) | Suspected (214) | NR | OR: Inpatient surgery(2.88) Dedicated center(2.76) Face masks not worn(3.34) Posterior capsule tear(3.82) Without subconjunctival antibiotics (6.85) | ECCE Phacoemulsification | A |
| Barry P, 2006 | ED | Coh | NR | Austria, Belgium, Germany, Italy, etc. | 2003∼ 2006 | 13 698 NR | 28(0.2%) | Suspected (28) | NR | OR: Without intracameral cefuroxime (4.59) | Phacoemulsification | A |
| Wu PC, 2006 | ED | CC | NR | Taiwan | 1992∼ 2000 | 10 614 NR | 12(0.113%) | Suspected (12) | NR | OR: skin preparation with 5% povidone-iodine(10.9) without 5% povidone-iodine conjunctival disinfection(5.6) | ECCE | B |
| Wejde G, 2005 | ED | CC | NR | Sweden | 1994∼ 2000 | 44 986 NR | 60(0.133%) | Suspected(60) | NR | RR: without intracameral cefuroxime(5.7) ECCE/ICCE(2.1) silicone lens((3.4) | ECCE Phacoemulsification | B |
| Lalitha P, 2005 | ED | RO | NR | India | 2002∼ 2003 | 36 072 NR | 19(0.053%) | Suspected(10) Confirmed(9) | NR | RR: posterior capsular rent(6.57) ECCE(4.9) older individuals(6.0) | ECCE Phacoemulsification | B |
| West ES, 2005 | ED | RO | NR | USA | 1994∼ 2001 | 477 627 NR | 1 026(0.215%) | Suspected(10) Confirmed(9) | NR | RR: surgeries before 1998(1.44) old individuals(90)(1.83) black race(1.30) | ECCE Phacoemulsification | A |
| Wallin T, 2005 | ED | Coh | NR | USA | 1996∼ 2002 | 1552 NR | 27(1.7%) | Suspected(27) | NR | RR: Wound leak(44) Capsular complication(17.2) Topical antibiotic after surgery(13.7) With ciprofloxacin (5.3) Without patching (7.1) Without collagen shield (2.7) | ECCE Phacoemulsification | B |
| Wejde G, 2005 | ED | PO | NR | Sweden | 1999∼ 2001 | 188 151 NR | 109(0.0595%) | Suspected (91) Confirmed (21) | GPB# | RR: Without intracameral cefuroxime (3.649) ECCE/ICCE (1.7) | ECCE Phacoemulsification | A |
| Li J, 2004 | W | PO | NR | Australia | 1980∼ 2000 | 117 083 NR | 210(0.179%) | Suspected (210) | NR | OR: Male 0.89(0.67–1.19) Older individuals(>80)1.50(1.13–1.99) Length of stay(+8days) (2.08) Private hospital (2.38) Length of study (>8days)(2.08) With vitreoretinal procedure (2.71) Lacrimal/eyelid procedures (23.5) | ECCE ICCE Phacoemulsification other cataract extraction/ lens-related procedures | A |
| Wong TY, 2004 | ED | PO | NR | Singapore | 1996∼ 2001 | 44 803 NR | 34(0.076%) | Suspected (34) Confirmed (21) | RR:Phacoemulsification (3.1) Posterior capsule rupture (8.0) | ECCE Phacoemulsification | A | |
| Wong TY, 2004 | ED | CC | 54∼80 | Singapore Chinese, Malay,etc. | 1996∼ 2001 | 136 NR | 34(NA) | Suspected (34) Confirmed (21) | Staphylococcus (13) Streptococci (1); P.aeroginosa(1) Others(6) | OR: Silicone IOL (5.1) Posterior capsular rupture (20.9) | ECCE Phacoemulsification | B |
| Cooper BA, 2003 | ED | CC | NR | USA | 1997∼ 2000 | 409 NR | 38(NA) | Confirmed(38) | NR | OR: Clear corneal incision (3.36) | ECCE Phacoemulsification | B |
| E Mayer, 2003 | ED | RO | NR | UK | 1991∼ 2001 | 18 191 (43–89) | 30(0.16%) | Suspected (30) Confirmed (26) | Staphylococcus (9) P. Streptococcus (2) P.aeruginosa (1) Others(14) | RR: ECCE (4.37) Folded IOL (43.8) Capsular rupture (2.06) | ECCE Phacoemulsification | B |
| Ellis MF, 2003 | ED | RO | NR | Australia | 1997∼ 2001 | 633 NR | 5(0.78%) | Confirmed (5) | S. epidermidis (5) | OR: Topical anesthesia (7.63) | Phacoemulsification | B |
| Nagaki Y, 2003 | ED | PO | NR | Japan | 1998∼ 2001 | 11595 NR | 16(0.14%) | Suspected (16) Confirmed (13) | NR | RR: Clear corneal incision (5.61) | Phacoemulsification | A |
| Kalpadakis P, 2002 | ED | RO | NR | Greece | 1998∼ 2001 | 2 446 NR | 20(0.82%) | Suspected (20) | NR | RR: ECCE (1.99) | ECCE Phacoemulsification | A |
| Montan P, 2002 | ED | PO | NR | Sweden | 1998 | 54 666 NR | 58(0.106%) | Suspected (58) Confirmed (41) | CNS #(15) Streptococci (12) S. aureus(4) | OR: PMMA (2.03) Silicon (1.93) Hydrogel (2.89) | Phaco + PC IOL ECCE + PC IOL Phaco/ECCE + AC IOL | A |
| Lertsumitkul S, 2001 | W | CC | NR | Australia | 1996∼ 1998 | 97 NR | 31(NA) | Suspected (31) Confirmed (20) | S. Epidermidis(9) S. aureus(5) Streptococcus(2) | OR: Surgical complications (6.34) Clear corneal temporal incision (3.52) | ECCE Phacoemulsification Penetrating keratoplasty | B |
| Colleaux KM, 2000 | ED | RO | NR | Sask | 1994∼ 1998 | 13 886 NR | 25 (0.18%) | Suspected (25) | NR | OR: without subconjunctival antibiotic injections (16.23) | Phacoemulsification | B |
| Swaddiwudhipong W, 2000 | ED | RO | NR | Thailand | 1997∼ 1998 | 329 NR | 31(9.4%) | Suspected (31) | NR | RR: ECCE (0.47) | Phacoemulsification145 ECCE165 secondary IOL implantation | B |
| Schmitz S, 1999 | ED | CS | NR | Germany | 1996 | 340 633 NR | 267 (0.148%) | NR | NR | OR: preoperative topical antibiotics (2.38) outpatient surgeries (2.0) | NA | A |
| Bainbridge JW, 1998 | ED | RO | 12∼101 | United Kingdom | NA | 772 NR | 7(0.91%) | Suspected (7) Confirmed(5) | CNS# (3) S. aureus(1) | RR: Silicone IOL (20.73) | Phacoemulsification | B |
| Norregaard JC, 1997 | ED | RO | NR | Denmark | 1985∼ 1987 | 19 246 NR | 61(0.317%) | Suspected (61) | NR | OR: Old individuals≥90 (3.62) Male gender (1.93) ICCE (2.22) Capsular rupture (4.86) | ECCE ± IOL ICCE ± IOL | B |
| Javitt JC, 1991 | ED | RO | NR | USA | 1984 | 324 032 NR | 439(0.135%) | Suspected(439) | NR | OR: Capsular rupture (4.56) Male gender (1.23) | ICCE 99971 ECCE 195587 Phacoemulsification 28474 | B |
| Authors, Year [Ref] | Data Source | Study Design | Presentation interval(days) | Country | Date | Population Sample size, age[yrs] | Total Number of endophthalmitis (incidence rate%) | Definition of the endophthalmitis | Type of confirmed pathogen (n) | Risk factors (RR/OR) & | Classification of cataract surgery | Quality Criteria? |
| Das T, 2012 | ED | CC | 15±12 | India | 1993∼ 1998 | 46 095 42∼81 | 62(0.13%) | Suspected (62) Confirmed (36) | S. Epidermidis(16); P. Aeruginosa(5); GPC (other)# (8) Others(7) | OR: Ambulatory patients care (3.63) Residence location within city(2.27) | ECCE Phacoemulsification | B |
| Keay L, 2012 | ED | RO | NR | USA | 2003∼ 2004 | 3 280 966 NA | 4 006 (0.012%) | Suspected (4006) | NR | RR: Male (1.23) Older individuals(≥85)(1.53) Black (1.17) Native Americans (1.72) Surgeons with low annual volume (3.8) Surgeons with less experience (1.41) surgeries performed in 2003 (1.2) | NA | B |
| Romero-Aroca P, 2012 | ED | PO | 5.37±2.33 | Spain | 1996∼ 2009 | 25 001 53∼89 | 83 (3.32%) | Suspected (83) Confirmed (55) | NR | RR: Without intracameral cefazolin (11.45) | Phacoemulsification | A |
| Tan CS, 2012 | ED | Coh | NR | Singapore | 11 years | 50 177 NR | 21(0.042%) | Suspected(21) | NR | OR: Without intracameral cefazolin (13.6) Age(1.05) Male gender(2.96) | NA | B |
| García-Sáenz MC 2010 | ED | CS | NR | Spain | 1999∼ 2009 | 15 173 NR | 43(0.28%) | Suspected (43) | NR | RR: Without intracameral cefuroxime (8.57) | NA | A |
| Anijeet DR, 2010 | ED | RO | 1∼14 | UK | 1998∼ 2008 | 16 606 NR | 14(0.078%) | Suspected(14) Confirmed(6) | GPC#(1); P. Streptococcus(3) P. aeruginosa (1); Nil(1) | RR: without intracameral vancomycin (38) | NA | B |
| Freeman EE 2010 | ED | RO | <90 | Canada | 1996∼ 2005 | 490 690 NR | 754(0.15%) | Suspected(754) | NR | OR:Older individuals(≥85)(1.34) Male gender(1.44) later year of surgery (0.94) Region of surgery 6 and 9(6∼9) | NA | B |
| Lloyd JC, 2009 | ED | RO | 1∼35 | Canada | 2006∼ 2005 | 13 931 NR | 5(0.036%) | Suspected(5) Confirmed(4) | Staphylococcus(2); Streptococcus(1);P.acnes(1); | OR:Without fourth-generation fluoroquinolones perioperatively(6.3) | Phacoemulsification | B |
| Al-Mezaine HS, 2009 | ED | RO | NR | Arabia | 10 | 29 412 NR | 20(0.068%) | Suspected(20) Confirmed(18) | Staphylococcus (7); Streptococcus(7); P.acnes(1); others(3) | OR:clear corneal incision(1.73) | ECCE Phacoemulsification | B |
| Garat M, 2009 | ED | CC | NR | Spain | 2002∼ 2007 | 18 579 NR | 31(0.167%) | Suspected(27) Confirmed(4) | NR | RR: Without intracameral cefazolin(8.89) | Phacoemulsification | B |
| Hatch WV, 2009 | ED | Coh | NR | Canada | 2002∼ 2006 | 442 177 NR | 617(0.14%) | Suspected(617) | NR | OR: Male gender(1.4) Capsular rupture(9.56) Older individuals(1.24) | ECCE Phacoemulsification | A |
| Pleyer U, 2008 | ED | Coh | NR | Europe | NR | 16211 NR | 29(0.179%) | Suspected(29) Confirmed(20) | NR | RR: Without intracameral cefuroxime(4.92) Clear corneal incision(5.88) Silicon based IOL(3.13) Intraoperative complications(4.95) | Phacoemulsification | A |
| Garcia-Arumi J, 2007 | ED | CC | <30 | Spain | 2002∼ 2003 | 5 011 NR | 27(0.539%) | NR | NR | OR: Topical anesthesia(11.8) Surgery longer than 45minutes(7.2) | NA | A |
| Endophthalmitis Study Group, 2007 | ED | Coh | NR | Austria, Belgium, Germany, Italy, etc. | NR | 16 603 NR | 29(0.175%) | Suspected(29) Confirmed(20) | NR | OR: Without intracameral cefuroxime (4.92) Clear corneal incision(5.88) Silicone IOL(3.13) Surgical complications(4.95) Male gender(2.70) | ECCE Phacoemulsification | A |
| Lundström M 2007 | ED | PO | NR | Sweden | 2002∼ 2004 | 225 471 NR | 109(0.048%) | Suspected(109) | NR | RR: Communication between the anterior and vitreous Older individuals (≥85) Without intracameral cefuroxime | ECCE Phacoemulsification | A |
| Ng JQ, 2007 | W | CC | NR | Australia | 1980∼ 2000 | 1 025 NR | 205(NA) | Suspected (205) | NR | RR: Same day surgery (2.27) Posterior capsule breach(13.57) Sub-conjunctival injection(0.46) | ECCE Phacoemulsification | B |
| Kamalarajah S, 2006 | ED | CC | NR | UK | 1999∼ 2000 | 659 (73.5–75) | 214(NA) | Suspected (214) | NR | OR: Inpatient surgery(2.88) Dedicated center(2.76) Face masks not worn(3.34) Posterior capsule tear(3.82) Without subconjunctival antibiotics (6.85) | ECCE Phacoemulsification | A |
| Barry P, 2006 | ED | Coh | NR | Austria, Belgium, Germany, Italy, etc. | 2003∼ 2006 | 13 698 NR | 28(0.2%) | Suspected (28) | NR | OR: Without intracameral cefuroxime (4.59) | Phacoemulsification | A |
| Wu PC, 2006 | ED | CC | NR | Taiwan | 1992∼ 2000 | 10 614 NR | 12(0.113%) | Suspected (12) | NR | OR: skin preparation with 5% povidone-iodine(10.9) without 5% povidone-iodine conjunctival disinfection(5.6) | ECCE | B |
| Wejde G, 2005 | ED | CC | NR | Sweden | 1994∼ 2000 | 44 986 NR | 60(0.133%) | Suspected(60) | NR | RR: without intracameral cefuroxime(5.7) ECCE/ICCE(2.1) silicone lens((3.4) | ECCE Phacoemulsification | B |
| Lalitha P, 2005 | ED | RO | NR | India | 2002∼ 2003 | 36 072 NR | 19(0.053%) | Suspected(10) Confirmed(9) | NR | RR: posterior capsular rent(6.57) ECCE(4.9) older individuals(6.0) | ECCE Phacoemulsification | B |
| West ES, 2005 | ED | RO | NR | USA | 1994∼ 2001 | 477 627 NR | 1 026(0.215%) | Suspected(10) Confirmed(9) | NR | RR: surgeries before 1998(1.44) old individuals(90)(1.83) black race(1.30) | ECCE Phacoemulsification | A |
| Wallin T, 2005 | ED | Coh | NR | USA | 1996∼ 2002 | 1552 NR | 27(1.7%) | Suspected(27) | NR | RR: Wound leak(44) Capsular complication(17.2) Topical antibiotic after surgery(13.7) With ciprofloxacin (5.3) Without patching (7.1) Without collagen shield (2.7) | ECCE Phacoemulsification | B |
| Wejde G, 2005 | ED | PO | NR | Sweden | 1999∼ 2001 | 188 151 NR | 109(0.0595%) | Suspected (91) Confirmed (21) | GPB# | RR: Without intracameral cefuroxime (3.649) ECCE/ICCE (1.7) | ECCE Phacoemulsification | A |
| Li J, 2004 | W | PO | NR | Australia | 1980∼ 2000 | 117 083 NR | 210(0.179%) | Suspected (210) | NR | OR: Male 0.89(0.67–1.19) Older individuals(>80)1.50(1.13–1.99) Length of stay(+8days) (2.08) Private hospital (2.38) Length of study (>8days)(2.08) With vitreoretinal procedure (2.71) Lacrimal/eyelid procedures (23.5) | ECCE ICCE Phacoemulsification other cataract extraction/ lens-related procedures | A |
| Wong TY, 2004 | ED | PO | NR | Singapore | 1996∼ 2001 | 44 803 NR | 34(0.076%) | Suspected (34) Confirmed (21) | RR:Phacoemulsification (3.1) Posterior capsule rupture (8.0) | ECCE Phacoemulsification | A | |
| Wong TY, 2004 | ED | CC | 54∼80 | Singapore Chinese, Malay,etc. | 1996∼ 2001 | 136 NR | 34(NA) | Suspected (34) Confirmed (21) | Staphylococcus (13) Streptococci (1); P.aeroginosa(1) Others(6) | OR: Silicone IOL (5.1) Posterior capsular rupture (20.9) | ECCE Phacoemulsification | B |
| Cooper BA, 2003 | ED | CC | NR | USA | 1997∼ 2000 | 409 NR | 38(NA) | Confirmed(38) | NR | OR: Clear corneal incision (3.36) | ECCE Phacoemulsification | B |
| E Mayer, 2003 | ED | RO | NR | UK | 1991∼ 2001 | 18 191 (43–89) | 30(0.16%) | Suspected (30) Confirmed (26) | Staphylococcus (9) P. Streptococcus (2) P.aeruginosa (1) Others(14) | RR: ECCE (4.37) Folded IOL (43.8) Capsular rupture (2.06) | ECCE Phacoemulsification | B |
| Ellis MF, 2003 | ED | RO | NR | Australia | 1997∼ 2001 | 633 NR | 5(0.78%) | Confirmed (5) | S. epidermidis (5) | OR: Topical anesthesia (7.63) | Phacoemulsification | B |
| Nagaki Y, 2003 | ED | PO | NR | Japan | 1998∼ 2001 | 11595 NR | 16(0.14%) | Suspected (16) Confirmed (13) | NR | RR: Clear corneal incision (5.61) | Phacoemulsification | A |
| Kalpadakis P, 2002 | ED | RO | NR | Greece | 1998∼ 2001 | 2 446 NR | 20(0.82%) | Suspected (20) | NR | RR: ECCE (1.99) | ECCE Phacoemulsification | A |
| Montan P, 2002 | ED | PO | NR | Sweden | 1998 | 54 666 NR | 58(0.106%) | Suspected (58) Confirmed (41) | CNS #(15) Streptococci (12) S. aureus(4) | OR: PMMA (2.03) Silicon (1.93) Hydrogel (2.89) | Phaco + PC IOL ECCE + PC IOL Phaco/ECCE + AC IOL | A |
| Lertsumitkul S, 2001 | W | CC | NR | Australia | 1996∼ 1998 | 97 NR | 31(NA) | Suspected (31) Confirmed (20) | S. Epidermidis(9) S. aureus(5) Streptococcus(2) | OR: Surgical complications (6.34) Clear corneal temporal incision (3.52) | ECCE Phacoemulsification Penetrating keratoplasty | B |
| Colleaux KM, 2000 | ED | RO | NR | Sask | 1994∼ 1998 | 13 886 NR | 25 (0.18%) | Suspected (25) | NR | OR: without subconjunctival antibiotic injections (16.23) | Phacoemulsification | B |
| Swaddiwudhipong W, 2000 | ED | RO | NR | Thailand | 1997∼ 1998 | 329 NR | 31(9.4%) | Suspected (31) | NR | RR: ECCE (0.47) | Phacoemulsification145 ECCE165 secondary IOL implantation | B |
| Schmitz S, 1999 | ED | CS | NR | Germany | 1996 | 340 633 NR | 267 (0.148%) | NR | NR | OR: preoperative topical antibiotics (2.38) outpatient surgeries (2.0) | NA | A |
| Bainbridge JW, 1998 | ED | RO | 12∼101 | United Kingdom | NA | 772 NR | 7(0.91%) | Suspected (7) Confirmed(5) | CNS# (3) S. aureus(1) | RR: Silicone IOL (20.73) | Phacoemulsification | B |
| Norregaard JC, 1997 | ED | RO | NR | Denmark | 1985∼ 1987 | 19 246 NR | 61(0.317%) | Suspected (61) | NR | OR: Old individuals≥90 (3.62) Male gender (1.93) ICCE (2.22) Capsular rupture (4.86) | ECCE ± IOL ICCE ± IOL | B |
| Javitt JC, 1991 | ED | RO | NR | USA | 1984 | 324 032 NR | 439(0.135%) | Suspected(439) | NR | OR: Capsular rupture (4.56) Male gender (1.23) | ICCE 99971 ECCE 195587 Phacoemulsification 28474 | B |
Note: ED, electronic database; W, Internet search; CC, case-control; Coh, cohort; CS, cross-sectional; RO, retrospective observational; PO, prospective observational; PK, Penetrating keratoplasty; ECCE, extracapsular cataract extraction; ICCE, intracapsular extraction; AC IOL: anterior chamber intraocular lens; PC IOL: posterior chamber intraocular lens; NA, not available; NR, not recorded; N, domain not addressed. *Results were put into meta-analysis & OR/RR with 95% confidence interval is for all suspected endophthalmitis cases, not limited the confirmed (culture-positive) endophthalmitis. # GPC: Gram-positive cocci other than S. epidermidis. GNB: Gram-negative bacilli other than P. aeruginosa. GPB: Gram-positive bacilli other than P. Acnes. CNS*: Coagulase negative staphylococci; ?The quality criteria: A = consistent level 1 studies (1a-c), B = consistent level 2 or 3 studies or extrapolations from level 1 studies(2a–c,3a–b) 1a,SR (with homogeneity) of RCTs; 1b: Individual RCT (with narrow Confidence Interval);1c: all or none; 2a: SR (with homogeneity) of cohort studies;2b: Individual cohort study (including low quality RCT; e.g., <80% follow-up);2c: “Outcomes” Research; Ecological studies;3a: SR (with homogeneity*) of case-control studies;3b: Individual Case-Control Study. All the included studies have no conflict of Interest.
Summary results from the meta-analysis.
| Risk factor | Prospective | Cross sectional | Retrospective | |||||
| n | Pooled odds ratio | n | Overall estimate | n | n | Overall estimate | ||
| Male gender | 6 | 1.41(1.22∼1.63) | 1 | 2.70(1.07∼6.80) | 0 | NA | 5 | 1.38(1.21∼1.58) |
| Older individuals (≥85 years) | 7 | 1.50(1.18∼1.91) | 0 | NA | 0 | NA | 7 | 1.50(1.18∼1.91) |
| Without intracameral cefazolin | 3 | 10.76(6.45∼17.95) | 1 | 11.45(5.73∼22.88) | 0 | NA | 2 | 9.97(4.66∼21.33) |
| Without intracameral cefuroxime | 6 | 5.48(3.79∼7.92) | 4 | 4.09(2.86∼5.84) | 1 | 8.55(6.21∼11.76) | 1 | 5.70(2.77∼11.75) |
| Posterior capsular rupture | 10 | 6.34(4.23∼9.52) | 1 | 3.82(1.67∼8.72) | 0 | NA | 9 | 6.82(4.41∼10.55) |
| Clear corneal incision | 6 | 3.60(2.05∼6.31) | 3 | 5.65(3.75∼8.52) | 0 | NA | 3 | 2.44(1.46∼4.09) |
| Silicone based IOL | 6 | 3.02(2.03∼4.49) | 3 | 2.35(1.67∼3.30) | 0 | NA | 3 | 4.64(2.25∼9.56) |
| Intraoperative complications | 3 | 5.29(2.73∼10.18) | 2 | 4.95(2.31∼10.63) | 0 | NA | 1 | 6.34(1.77∼22.67) |
| ECCE/ICCE | 6 | 2.19(1.40∼3.24) | 0 | NA | 0 | NA | 6 | 2.19(1.40∼3.24) |
n = number of estimates entered in the models; NA: not available.
Funnel plots were reviewed for each risk factors and no evidence of publication bias was observed.
Figure 2Pooled odds ratio for acute endophthalmitis and by age (≥85 years vs.<85 years).
Figure 3Pooled odds ratio for acute endophthalmitis by gender (male vs. female).
Figure 4Pooled odds ratio for acute endophthalmitis by extra- or intracapsular cataract extraction (vs. phacoemulsification).
Figure 5Pooled odds ratio for acute endophthalmitis by a clear corneal incision (vs. sclerocorneal incision or scleral tunnel incision).
Figure 6Pooled odds ratio for acute endophthalmitis by without intracameral cefazolin.
Figure 7Pooled odds ratio for acute endophthalmitis by without intracameral cefuroxime.
Figure 8Pooled odds ratio for acute endophthalmitis by posterior capsular rupture.
Figure 9Pooled odds ratio for acute endophthalmitis by silicone based IOLs (compared with PMMA or acrylic IOLs).
Figure 10Pooled odds ratio for acute endophthalmitis by intraoperative complications.